# Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab

> **NCT02845999** · PHASE1 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 9 (actual)

## Conditions studied

- Gastrointestinal Metastatic Cancer

## Interventions

- **BIOLOGICAL:** allogenic immunotherapy based on Natural Killer cells adoptive transfer
- **BIOLOGICAL:** cetuximab
- **DRUG:** Cyclophosphamide
- **DRUG:** fludarabine
- **DRUG:** interleukin-2

## Key facts

- **NCT ID:** NCT02845999
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-01
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2016-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02845999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02845999, "Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02845999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*